Zhejiang Hisoar Pharmaceutical Co., Ltd.: history, ownership, mission, how it works & makes money

From a Taizhou workshop founded in 1966 to a Shenzhen-listed company under ticker 002099.SZ, Zhejiang Hisoar Pharmaceutical has grown through strategic diversification (1997), production alliances with Boehringer Ingelheim (2008) and a landmark 20‑year supply agreement with Pfizer in 2012, building manufacturing sites in Taizhou and Jiangsu Yancheng, a workforce of about 2,611 and an R&D team of 426 that supports more than 40 patents; the firm reported sales of RMB 1.074 billion in 2010 and CNY 1,922.03 million in 2024 (with a net loss of CNY 330.27 million), exports over 70% of its pharmaceutical products, supplies Penem and Clindamycin series globally, sells dyestuffs and intermediates to 30+ countries, holds EU CEP and Japanese GMP certifications, and monetizes through API and formulation sales, contract manufacturing, environmental equipment and medical supplies-an operationally integrated, innovation-driven business model that anchors its position among China's top 100 pharmaceutical innovators.

Zhejiang Hisoar Pharmaceutical Co., Ltd. (002099.SZ): Intro

• Founded: 1966 in Taizhou, Zhejiang Province
• Listed: Shenzhen Stock Exchange (ticker 002099.SZ)
• Core businesses: APIs, antibiotic products, speciality raw drugs, fine chemicals, contract manufacturing

• 1966 - Company established in Taizhou, Zhejiang Province, entering the pharmaceutical industry.
• 1997 - Expanded operations to include production of fine chemicals and special raw drugs, diversifying the product portfolio beyond traditional pharmaceuticals.
• 2008 - Formed a strategic production alliance with Boehringer Ingelheim and invested in new production facilities in Chuannan, Zhejiang Province to enhance manufacturing capacity and quality control.
• 2010 - Reported sales revenues of RMB 1.074 billion, reflecting significant commercial scale and market presence.
• 2012 - Entered a 20-year supply agreement to provide antibiotic products to Pfizer Asia Manufacturing Pte Ltd., integrating into global pharmaceutical supply chains and securing long-term demand.
• 2019 - Recognized among the top 100 innovative enterprises in China's pharmaceutical industry, underscoring its R&D investments and innovation capability.

• Mission: Develop and manufacture safe, effective pharmaceutical ingredients and formulations to support global healthcare (see detailed corporate statements: Mission Statement, Vision, & Core Values (2026) of Zhejiang Hisoar Pharmaceutical Co., Ltd.).
• Vision: Be a reliable global supplier of high-quality APIs and specialty chemicals while advancing R&D and sustainable manufacturing.
• Strategic priorities: Expand contract manufacturing, strengthen long-term supply agreements, invest in process R&D and regulatory compliance, and pursue vertical integration across API-to-formulation value chains.

• Integrated manufacturing footprint: multiple production sites (including Chuannan facilities) producing APIs, intermediates, and finished products with GMP-compliant lines.
• Technology & quality: Production alliances and long-term contracts with multinational pharma required upgrades to quality systems (e.g., EU/US/Pfizer supplier standards), driving capital investment in new plants and analytical labs.
• R&D pipeline: In-house process chemistry and formulation teams focused on cost-efficient synthesis, impurity control, and scale-up for commercial supply.
• Sales & distribution: Mix of direct sales to domestic pharmacies/wholesalers and long-term B2B supply contracts with multinational manufacturers and contract manufacturers (CMOs).

• Reported sales (2010): RMB 1.074 billion.
• Long-term contracts: 20-year supply agreement with Pfizer Asia Manufacturing (from 2012).
• Strategic investments: 2008 Chuannan facility expansion with Boehringer Ingelheim partnership to increase GMP production capacity.
• Recognition: Listed among China's top 100 innovative pharmaceutical enterprises (2019), indicating R&D intensity and IP output relative to peers.

Zhejiang Hisoar Pharmaceutical Co., Ltd. (002099.SZ): History

• Public listing: Shenzhen Stock Exchange - ticker 002099.
• Employee base: ~2,611 employees (most recent public disclosure).
• Subsidiaries (key operating arms): Zhejiang Hisoar Chuannan Pharmaceutical Co., Ltd.; Shanghai Hisoar Pharmaceutical Technology Development Co., Ltd.; Taizhou Gangxiang Technology Co., Ltd.
• Management team: General Manager & Director Guorui Xu; Vice President & CFO Bing Yao; Deputy General Manager Wen Hua Mao; Board Secretary Kang Yan.
• Ownership profile: Diverse shareholder base; specific major-holder breakdown not publicly disclosed in detail.
• Ownership/structure dynamics: Company has implemented ownership and structural changes over time to support strategy, financing and operational scaling.

• How it makes money: revenue primarily from manufacture and sale of pharmaceutical products (ethical medicines, formulations and related contract manufacturing and technology services) via its subsidiaries and domestic distribution channels.
• Strategic levers historically used: product portfolio expansion, capacity scaling through subsidiaries, selective M&A/ownership adjustments, and strengthening financial/operational management under the listed-company framework.

Zhejiang Hisoar Pharmaceutical Co., Ltd. (002099.SZ): Ownership Structure

• Mission: To be a widely trusted pharmaceutical enterprise in China delivering excellence in products and services and contributing to the health undertaking of human society.
• Core values: Faithfulness, cooperation, enterprise and elaboration guide governance, production and customer relations.
• Commitment to health: Focus on improving public health through pharmaceutical product development and distribution.
• Innovation: Ongoing investment in R&D to create high‑quality pharmaceutical offerings and maintain regulatory compliance across markets.
• Global outreach: More than 70% of pharmaceutical product sales are exported, reflecting a strong international footprint.
• Sustainability: Production lines include environmental-protection equipment and medical chemical supplies to align operations with sustainable practices.

• R&D and quality: Multi-site R&D capabilities, with investment allocated annually to formulation improvement, process optimization and regulatory dossiers for export markets.
• Manufacturing footprint: Integrated chemical and pharmaceutical production facilities producing APIs, intermediates and finished dosage forms for domestic and overseas customers.

• How it makes money: sale of APIs and finished drugs to domestic and international customers; contract manufacturing and long‑term supply agreements; export-driven sales (majority share), plus revenue from environmental protection equipment and chemical supplies.
• Ownership orientation: publicly listed entity (SZSE: 002099) with a mix of institutional investors, corporate strategic shareholders and free float on the Shenzhen market, governed by a board that aligns strategy with its mission and export-led business model.

Zhejiang Hisoar Pharmaceutical Co., Ltd. (002099.SZ): Mission and Values

• Core mission: Ensure patient safety and access through rigorous quality systems and continuous R&D investment.
• Values: Compliance (GMP/EHS), innovation (patent development), integration (supply‑chain control), and export‑oriented manufacturing.

• Manufacturing footprint:
  • Primary production sites include Taizhou (Zhejiang) and Yancheng (Jiangsu), enabling capacity redundancy and regional logistics efficiencies.
• Product range:
  • APIs and intermediates: antibiotics, cardiovascular agents, hypoglycemic agents, fine chemicals.
  • Finished formulations: a range of dosage forms for domestic prescription and OTC markets.
  • Specialties: dyestuffs and other fine‑chemical products supporting both pharmaceutical and industrial customers.
• Research & development:
  • R&D headcount: over 426 dedicated R&D staff.
  • Intellectual property: more than 40 patents held across APIs, processes and formulations.
• Quality control and compliance:
  • Quality systems: certified and operated under GMP and EHS frameworks to ensure product safety and regulatory compliance.
  • Global certifications: EU CEP (Certificate of Suitability/COS) and passed Japanese GMP inspections, supporting exports to stringent regulatory jurisdictions.
• Supply chain and integration:
  • Vertically integrated model from raw‑material synthesis, in‑house intermediate processing, to formulation and finished‑goods distribution-reducing third‑party dependence and improving margin control.

• API and intermediate sales: bulk production sold to domestic formulators and international generic manufacturers.
• Finished formulations: branded and generic drug sales through hospitals, pharmacies and distribution partners in China.
• Export sales: regulated‑market exports enabled by CEPS/COS and Japanese GMP acceptance for higher‑margin international contracts.
• Contract manufacturing and custom synthesis: fee‑based revenue from third‑party clients for specialized API/intermediate production.
• Specialty chemical sales: dyestuffs and fine chemicals sold to industrial customers as a complementary revenue stream.

Zhejiang Hisoar Pharmaceutical Co., Ltd. (002099.SZ): How It Works

• Core manufacturing: multi-site API and formulation production under GMP standards.
• R&D and quality control: in-house labs for process development, stability testing, and regulatory dossiers.
• Contract manufacturing & supply: long-term supply agreements and CMOs with multinational pharma companies.
• Export logistics & compliance: regulatory support for markets across Europe, North America, and Asia.

• Pharmaceutical sales - primary revenue driver: finished formulations and APIs sold domestically and internationally; driven by scale production and export contracts.
• Export market intensity - >70% of pharmaceutical products exported, forming the bulk of foreign sales and FX-denominated income.
• Dyestuff & intermediates - diversified chemical business, exported to more than 30 countries and regions, contributing a meaningful secondary revenue stream.
• Environmental equipment - design, manufacture and sale of pollution-control and process equipment to industrial customers.
• Medical supplies & appliances - production of chemical medical consumables and devices, expanding non-prescription revenues.
• Strategic partnerships - contract manufacturing and supply agreements with global firms (e.g., Pfizer, Boehringer Ingelheim) that stabilize order flow and unit economics.

• Export intensity: >70% of pharmaceutical product volumes destined for international markets.
• Global reach: dyestuff and intermediate exports to more than 30 countries and regions.
• Partnerships: active CMOs and supply relationships with multinational pharma firms (examples include Pfizer and Boehringer Ingelheim), providing recurring bulk order revenue.
• Margin levers: scale manufacturing, vertical integration (raw intermediates → APIs → formulations), and contract manufacturing improve gross margins and utilization.

• Large-volume contracts and export orders generate predictable cash receipts and foreign-currency inflows.
• Value-add transition from selling intermediates to APIs and finished formulations increases realized price per kg and margins.
• Dyestuff exports and environmental-equipment projects provide counter-cyclical revenue during pharma demand fluctuations.
• Ongoing R&D and regulatory filings enable entry into adjacent therapeutic segments and higher-value product registrations.

Zhejiang Hisoar Pharmaceutical Co., Ltd. (002099.SZ): How It Makes Money

• Core revenue drivers: sales of finished dosage forms (injectables, oral preparations) and active pharmaceutical ingredients (APIs) for Penem and Clindamycin classes.
• R&D-driven specialty products and licensed technologies that generate royalties and collaboration income.
• Contract manufacturing and export sales to international distributors and hospitals.
• Government and institutional tenders for hospital-use antibiotics.

• Market expansion strategy: entering new geographic markets, deepening distributor networks, and pursuing regulatory clearances for additional countries.
• Sustainability & compliance: investments in cleaner production and waste treatment to meet tightening international standards, which protect market access.